Diligence memo · auto-generated · as of July 2, 2026

Ambio Holdings, Inc.

Ambio Holdings, Inc. looks fair against its niche peers and is dormant on financing cadence.

DeprioritizeFinancing has gone silent well past the sector's normal cadence — treat as inactive until outside confirmation of a live operation.

Businessfiled

Ambio Holdings, Inc. operates in Biotechnology, based in NORTH AUGUSTA.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Ambio Holdings, Inc. has raised $24M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).

Largest single filing: $24M on 2014-11-05.

Most recent recorded round closed around 2014-11-05.

Valuation (modeled)modeled

Provath models Ambio Holdings, Inc. at approximately $953M (range $48M–$3.7B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Fair. Modeled value is 1.33× the median modeled value of Series B Biotechnology companies in 2013–2015 (77 peers) — value vs value, same stage and era. Within the normal band (133% of peer median) for its niche.

Financing rhythm & timingmixed

Last raise 11.7 yr ago; this sector typically re-raises about every 14 months.

Only one round on record and long silent — often defunct, acquired, or gone quiet.

Comparablesmixed

Capital scale ranks ahead of 71% of Biotechnology peers (4293 compared).

Modeled value ranks above 89% of those peers.

Closest niche peers: BioAtla,LLC, Scholar Rock LLC, Oligasis, LLC, Alector LLC, Gelesis Inc.

Peoplefiled

5 named people on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.